Aion Therapeutic (XCNQ:AION) Scaled Net Operating Assets: -1.22 (As of Jan. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aion Therapeutic Scaled Net Operating Assets?

Aion Therapeutic XCNQ:AION Scaled Net Operating Assets is -1.22 as of Jan. 2025.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Aion Therapeutic's operating assets for the quarter that ended in Jan. 2025 was C$1.19 Mil. Aion Therapeutic's operating liabilities for the quarter that ended in Jan. 2025 was C$3.07 Mil. Aion Therapeutic's Total Assets for the quarter that ended in Oct. 2024 was C$1.54 Mil. Therefore, Aion Therapeutic's scaled net operating assets (SNOA) for the quarter that ended in Jan. 2025 was -1.22.


Aion Therapeutic Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Aion Therapeutic's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aion Therapeutic Scaled Net Operating Assets Chart

Aion Therapeutic Annual Data
Trend Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Scaled Net Operating Assets
Get a 7-Day Free Trial 0.60 0.22 -1.04 -11.70 -8.82

Aion Therapeutic Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.24 -0.32 -2.32 -1.48 -1.22

XCNQ:AION vs CBDY, GRPS, PLSH: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aion Therapeutic's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aion Therapeutic Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aion Therapeutic's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Aion Therapeutic's Scaled Net Operating Assets falls into.



Aion Therapeutic Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Aion Therapeutic's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Apr. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Apr. 2024 )
=(Operating Assets (A: Apr. 2024 )-Operating Liabilities (A: Apr. 2024 ))/Total Assets (A: Apr. 2023 )
=(0.634525-2.493171)/0.210672
=-8.82

where

Operating Assets(A: Apr. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=0.702861 - 0.068336
=0.634525

Operating Liabilities(A: Apr. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=4.57471 - 0 - 2.081539
=2.493171

Aion Therapeutic's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jan. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jan. 2025 )
=(Operating Assets (Q: Jan. 2025 )-Operating Liabilities (Q: Jan. 2025 ))/Total Assets (Q: Oct. 2024 )
=(1.19256-3.069715)/1.54164
=-1.22

where

Operating Assets(Q: Jan. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1.20638 - 0.01382
=1.19256

Operating Liabilities(Q: Jan. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=5.879066 - 0 - 2.809351
=3.069715

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -1.22 mean?
Aion Therapeutic (XCNQ:AION) has a Scaled Net Operating Assets of -1.22 as of Jan. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Aion Therapeutic and its competitors.
Is Aion Therapeutic's Scaled Net Operating Assets too high?
Aion Therapeutic's current Scaled Net Operating Assets is -1.22.
How does Aion Therapeutic's Scaled Net Operating Assets compare to CBDY and GRPS?
Aion Therapeutic's Scaled Net Operating Assets of -1.22 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Aion Therapeutic and its competitors. Aion Therapeutic's current Scaled Net Operating Assets is -1.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aion Therapeutic stock overvalued right now?
Aion Therapeutic (XCNQ:AION) has a current Scaled Net Operating Assets of -1.22. The current Scaled Net Operating Assets is -1.22. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Aion Therapeutic (XCNQ:AION), the current Scaled Net Operating Assets is -1.22 as of Jan. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aion Therapeutic Business Description

Address 700 West Georgia Street, Suite 2200, Vancouver, BC, CAN, V7Y 1K8
Aion Therapeutic Inc is in the business of research and development, treatment, data mining, and state of the art artificial intelligence techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals utilizing compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations, and other medicinal plants in a legal environment for this type of discovery. During the year ended the Company had one operating segment, being health and wellness, dedicated to delivering state-of-the-art water filtration solutions. Geographically company earns revenue from USA.